| [1] |
Asakura H. Thrombosis in myeloproliferative neoplasms[J]. Rinsho Ketsueki, 2018, 59(8): 1034-1041.
|
| [2] |
孙秉中. 真性红细胞增多症的诊断与治疗[C]. 中华医学会第十一次全国血液学学术会议论文集. 西安, 2010: 18-23.
|
| [3] |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-405.
doi: 10.1182/blood-2016-03-643544
pmid: 27069254
|
| [4] |
Spivak JL. Polycythemia vera[J]. Curr Treat Options Oncol, 2018, 19(2): 12.
doi: 10.1007/s11864-018-0529-x
|
| [5] |
Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012: 571-81.
doi: 10.1182/asheducation-2012.1.571
pmid: 23233637
|
| [6] |
Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis[J]. Curr Hematol Malig Rep, 2017, 12(5): 389-396.
doi: 10.1007/s11899-017-0400-3
URL
|
| [7] |
Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F[J]. Semin Thromb Hemost, 2007, 33(4): 313-320.
pmid: 17525888
|
| [8] |
Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation[J]. J Clin Invest, 2018, 128(10): 4359-4371.
doi: 10.1172/JCI90312
pmid: 30024857
|
| [9] |
Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms[J]. Sci Transl Med, 2018, 10(436): eaan8292.
|
| [10] |
Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms[J]. Proc Natl Acad Sci U S A, 2014, 111(6): 2295-2300.
doi: 10.1073/pnas.1312148111
URL
|
| [11] |
Iurlo A, Cattaneo D, Bucelli C, et al. New perspectives on polycythemia vera: from diagnosis to therapy[J]. Int J Mol Sci, 2020, 21(16): 5805.
doi: 10.3390/ijms21165805
URL
|
| [12] |
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(12): 1599-1613.
doi: 10.1002/ajh.v95.12
URL
|
| [13] |
Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet[J]. J Clin Oncol, 2011, 29(6): 761-770.
doi: 10.1200/JCO.2010.31.8436
pmid: 21205761
|
| [14] |
中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(4): 265-268.
|
| [15] |
How J, Hobbs G. Management issues and controversies in low-risk patients with essential thrombocythemia and polycythemia vera[J]. Curr Hematol Malig Rep, 2021, 16(5): 473-482.
doi: 10.1007/s11899-021-00649-x
|
| [16] |
Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera[J]. J Clin Oncol, 2005, 23(10): 2224-2232.
doi: 10.1200/JCO.2005.07.062
pmid: 15710945
|
| [17] |
Zwicker JI, Paranagama D, Lessen DS, et al. Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study[J]. Haematologica, 2022, 107(5): 1106-1110.
doi: 10.3324/haematol.2021.279032
URL
|
| [18] |
Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia[J]. Intern Emerg Med, 2010, 5(3): 177-184.
doi: 10.1007/s11739-009-0319-3
pmid: 19789961
|
| [19] |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性脑梗死后出血转化诊治共识2019[J]. 中华神经科杂志, 2019, 52(4): 252-265.
|
)
